Delcath Systems (NASDAQ:DCTH) Rating Lowered to Sell at StockNews.com

Delcath Systems (NASDAQ:DCTH) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Thursday.

DCTH has been the topic of a number of other research reports. Stephens reissued an “overweight” rating and issued a $25.00 price objective on shares of Delcath Systems in a research note on Tuesday, August 6th. Craig Hallum began coverage on Delcath Systems in a research report on Friday, June 28th. They set a “buy” rating and a $18.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $22.00 target price on shares of Delcath Systems in a research report on Tuesday, August 6th.

Delcath Systems Stock Performance

DCTH opened at $9.00 on Thursday. Delcath Systems has a one year low of $2.25 and a one year high of $11.74. The stock’s fifty day moving average is $8.81 and its 200-day moving average is $7.06. The company has a market capitalization of $250.07 million, a PE ratio of -3.40 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH) last posted its quarterly earnings data on Monday, August 5th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative return on equity of 312.48% and a negative net margin of 474.22%. The firm had revenue of $7.77 million during the quarter, compared to the consensus estimate of $5.00 million. During the same period in the prior year, the firm posted ($0.58) EPS. On average, equities research analysts forecast that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Delcath Systems

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Rosalind Advisors Inc. raised its position in shares of Delcath Systems by 155.1% during the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock worth $22,184,000 after purchasing an additional 1,611,561 shares during the period. AIGH Capital Management LLC boosted its position in Delcath Systems by 1.7% during the 2nd quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock worth $20,086,000 after acquiring an additional 40,064 shares during the period. BVF Inc. IL grew its stake in Delcath Systems by 23.1% during the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after acquiring an additional 225,918 shares in the last quarter. Vanguard Group Inc. increased its stake in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after buying an additional 161,678 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in Delcath Systems in the 4th quarter worth approximately $962,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.